Kraft Group has once again participated in a funding round for the RNA drug developer, having backed its series A round three years ago.
US-based programmable therapeutics developer Camp4 secured $45m yesterday from investors including conglomerate Kraft Group.
The round was co-led by 5AM Ventures and Northpond Ventures, while fellow venture capital firms Andreessen Horowitz and Polaris Partners also took part along with undisclosed existing backers.
Camp4 is developing programmable and precise therapeutics designed to treat a range of diseases including Dravet Syndrome and Urea cycle disorder. Its drug candidates target a class of ribonucleic acid (RNA) known as regulatory RNAs that control the…
